U.S. markets open in 2 hours 26 minutes
  • S&P Futures

    3,665.00
    -2.25 (-0.06%)
     
  • Dow Futures

    29,836.00
    -32.00 (-0.11%)
     
  • Nasdaq Futures

    12,474.50
    +20.25 (+0.16%)
     
  • Russell 2000 Futures

    1,834.60
    -2.90 (-0.16%)
     
  • Crude Oil

    44.96
    -0.32 (-0.71%)
     
  • Gold

    1,844.60
    +14.40 (+0.79%)
     
  • Silver

    24.32
    +0.24 (+1.00%)
     
  • EUR/USD

    1.2127
    +0.0012 (+0.10%)
     
  • 10-Yr Bond

    0.9480
    0.0000 (0.00%)
     
  • Vix

    20.91
    +0.14 (+0.67%)
     
  • GBP/USD

    1.3439
    +0.0064 (+0.48%)
     
  • USD/JPY

    104.2900
    -0.1340 (-0.13%)
     
  • BTC-USD

    19,386.88
    +437.63 (+2.31%)
     
  • CMC Crypto 200

    381.18
    +16.26 (+4.46%)
     
  • FTSE 100

    6,469.92
    +6.53 (+0.10%)
     
  • Nikkei 225

    26,809.37
    +8.39 (+0.03%)
     

NEOGEN (NEOG), Transnetyx Partner to Advance Mouse Genotyping

Zacks Equity Research
·4 min read

NEOGEN Corporation NEOG recently entered into a partnership with Transnetyx, Inc. to collaborate on distribution and advancement of the miniMUGA genotyping array (Mouse Universal Genotyping Array). Notably, NEOGEN aims to leverage Transnetyx’s wide-reaching footprint in the model organism community via the collaboration.

For investors’ note, the miniMUGA is the fourth iteration of NEOGEN’s murine (relating to or affecting mice or related rodents) genotyping portfolio. Further, miniMUGA differs from the previous versions as it was specifically designed for quality control applications.

With the recent collaboration, NEOGEN aims to strengthen its Genomics business on a global scale. Notable, the Genomics business is a part of its broader Animal Safety arm.

Rationale Behind the Collaboration

The miniMUGA array, powered by NEOGEN Genomics, was developed by researchers at the University of North Carolina Chapel Hill. The panel contains numerous markers that can be used to determine the genetic background in over 241 inbred mice. It aims to provide a valuable platform for genetic QC and a vital new tool to increase rigor and reproducibility of mouse biomedical research. The partnership is aimed at providing the biomedical research community with a comprehensive and affordable solution for testing the genetic background of their mouse models.

Per NEOGEN’s management, the partnership will serve the whole biomedical research community via the combined expertise of Transnetyx and NEOGEN’s expertise in the development of genomic solutions.

Industry Prospects

Per a report by Research And Markets, the global mice model market size is projected to reach $1.9 billion by 2025 from $1.4 billion in 2020 at a CAGR of 6.4%. Factors like increasing implications of mouse clinical trials for more predictive outcomes and growing R&D expenses in the pharmaceutical & biopharmaceutical industries are likely to drive the market.

Given the market potential, the collaboration seems to have been timed well.

Recent Developments in Animal Safety

Of late, NEOGEN has been witnessing a slew of developments within its Animal Safety segment.

The company, this month, launched a foaming antibacterial hand soap, COMPANION Foaming Antibacterial Hand Soap, which is highly effective against harmful bacteria and is skin-friendly.

NEOGEN, in October, launched the Igenity Feeder, which is a DNA tool designed to assist cattle producers in the stocker and backgrounder phase to rank and manage feeder cattle according to their genetic potential for carcass traits.

In August, NEOGEN received the Organic Materials Review Institute’s certification stating that its AquaPrime Peraside 15 is in compliance with the USDA National Organic Program, with usage restrictions. The same month, the Environmental Protection Agency validated the effectiveness of NEOGEN’s BioSentry 904 Disinfectant against the COVID-19-causing SARS-CoV-2 virus, when used per the revised label instructions.

Price Performance

Shares of the company have gained 11.5% in the past year compared with the industry’s 5.3% rise and the S&P 500’s 16% growth.

Zacks Rank & Key Picks

Currently, NEOGEN carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are ResMed Inc. RMD, Thermo Fisher Scientific Inc. TMO and Align Technology, Inc. ALGN.

ResMed’s long-term earnings growth rate is estimated at 14.5%. The company presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Thermo Fisher’s long-term earnings growth rate is estimated at 18%. It currently carries a Zacks Rank #2.

Align Technology’s long-term earnings growth rate is estimated at 18.3%. It currently carries a Zacks Rank #2.

5 Stocks Set to Double

Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
ResMed Inc. (RMD) : Free Stock Analysis Report
 
Align Technology, Inc. (ALGN) : Free Stock Analysis Report
 
Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report
 
Neogen Corporation (NEOG) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research